Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- April 18, 2024 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 8:45 AM

-- April 15, 2024 --

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs Globe Newswire 8:55 AM

-- April 11, 2024 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 11:00 AM

-- April 10, 2024 --

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Globe Newswire 8:21 AM

-- April 2, 2024 --

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- March 28, 2024 --

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference Globe Newswire 8:05 AM

-- March 26, 2024 --

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast Globe Newswire 9:05 AM

-- March 25, 2024 --

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Globe Newswire 9:05 AM

-- March 22, 2024 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 8:55 AM

-- March 20, 2024 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 9:25 AM

-- March 15, 2024 --

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity Globe Newswire 8:45 AM

-- March 7, 2024 --

AIM ImmunoTech Announces Launch of CEO Corner Platform Globe Newswire 8:45 AM

-- February 29, 2024 --

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update Globe Newswire 8:45 AM

-- February 14, 2024 --

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:55 AM

-- February 8, 2024 --

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Globe Newswire 8:50 AM

-- January 24, 2024 --

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer Globe Newswire 9:10 AM

-- January 22, 2024 --

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca's Imfinzi for the Treatment of Late-Stage Pancreatic Cancer Globe Newswire 8:55 AM

-- January 10, 2024 --

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:45 AM

-- January 5, 2024 --

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting Business Wire 1:32 PM

-- January 3, 2024 --

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied PRNewswire 4:05 PM

-- December 29, 2023 --

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board's Determination that Activist Group's Nominations Are Invalid Business Wire 8:00 AM

-- November 28, 2023 --

AIM ImmunoTech Provides Update Regarding Annual Meeting Business Wire 4:30 PM

-- November 27, 2023 --

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen with Issuance of Two Key U.S. Patents Globe Newswire 9:05 AM

-- November 21, 2023 --

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Globe Newswire 12:00 PM